BioCryst Pharmaceuticals
BCRX
BCRX
221 hedge funds and large institutions have $1.61B invested in BioCryst Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 70 increasing their positions, 61 reducing their positions, and 51 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
5% less funds holding
Funds holding: 233 → 221 (-12)
16% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 51
23% less capital invested
Capital invested by funds: $2.09B → $1.61B (-$488M)
Holders
221
Holding in Top 10
6
Calls
$51.3M
Puts
$26.8M
Top Buyers
| 1 | +$48.9M | |
| 2 | +$38.8M | |
| 3 | +$37.5M | |
| 4 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$35.4M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$32.9M |
Top Sellers
| 1 | -$38.3M | |
| 2 | -$37.7M | |
| 3 | -$34.1M | |
| 4 |
DM
Deerfield Management
New York
|
-$16.5M |
| 5 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$11.8M |